Cara Therapeutics IncNASDAQ:CARANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7782
- TODAY'S CHANGE (%)0.0060 (0.7770%)
- Bid / Lots0.7715/ 1
- Ask / Lots0.7815/ 1
- Open / Previous Close0.7969 / 0.7722
- Day Range
- 52 Week Range
- Volume159,125
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CARA |
|---|---|---|
| 09:32 ET | 11298 | 0.7906 |
| 09:34 ET | 598 | 0.795 |
| 09:39 ET | 600 | 0.7946 |
| 09:41 ET | 3775 | 0.77485 |
| 09:43 ET | 100 | 0.7755 |
| 09:45 ET | 5660 | 0.7925 |
| 09:48 ET | 2100 | 0.7838 |
| 09:52 ET | 100 | 0.7925 |
| 09:54 ET | 300 | 0.7924 |
| 09:56 ET | 100 | 0.7751 |
| 09:57 ET | 100 | 0.7755 |
| 09:59 ET | 100 | 0.7755 |
| 10:03 ET | 722 | 0.7756 |
| 10:06 ET | 1080 | 0.7571 |
| 10:08 ET | 108 | 0.76845 |
| 10:12 ET | 103 | 0.76845 |
| 10:15 ET | 100 | 0.768449 |
| 10:17 ET | 100 | 0.76845 |
| 10:19 ET | 12000 | 0.77479 |
| 10:24 ET | 100 | 0.7571 |
| 10:28 ET | 500 | 0.773512 |
| 10:30 ET | 425 | 0.7571 |
| 10:39 ET | 100 | 0.76 |
| 10:42 ET | 100 | 0.7775 |
| 10:46 ET | 1941 | 0.7775 |
| 10:53 ET | 600 | 0.7627 |
| 11:04 ET | 100 | 0.7775 |
| 11:08 ET | 100 | 0.7701 |
| 11:09 ET | 100 | 0.7627 |
| 11:15 ET | 100 | 0.7775 |
| 11:27 ET | 3026 | 0.7775 |
| 11:29 ET | 700 | 0.7716 |
| 11:31 ET | 7800 | 0.7825 |
| 11:33 ET | 600 | 0.784 |
| 11:42 ET | 658 | 0.7875 |
| 11:44 ET | 1350 | 0.7859 |
| 11:45 ET | 100 | 0.7945 |
| 11:47 ET | 1950 | 0.7859 |
| 11:56 ET | 300 | 0.7806 |
| 11:58 ET | 161 | 0.7828 |
| 12:02 ET | 100 | 0.7805 |
| 12:12 ET | 291 | 0.7769 |
| 12:14 ET | 800 | 0.7716 |
| 12:20 ET | 200 | 0.7716 |
| 12:27 ET | 100 | 0.7716 |
| 12:30 ET | 100 | 0.7716 |
| 12:32 ET | 1400 | 0.78 |
| 12:34 ET | 175 | 0.775 |
| 12:43 ET | 200 | 0.7716 |
| 12:50 ET | 700 | 0.7725 |
| 12:54 ET | 100 | 0.7733 |
| 12:56 ET | 3813 | 0.775 |
| 12:57 ET | 1000 | 0.775 |
| 12:59 ET | 850 | 0.7774 |
| 01:01 ET | 2225 | 0.78 |
| 01:03 ET | 2405 | 0.7801 |
| 01:06 ET | 285 | 0.7825 |
| 01:08 ET | 600 | 0.7821 |
| 01:10 ET | 600 | 0.7797 |
| 01:12 ET | 735 | 0.777 |
| 01:14 ET | 400 | 0.7797 |
| 01:15 ET | 520 | 0.7797 |
| 01:19 ET | 100 | 0.7797 |
| 01:21 ET | 400 | 0.7769 |
| 01:24 ET | 100 | 0.7825 |
| 01:32 ET | 100 | 0.7825 |
| 01:33 ET | 838 | 0.7769 |
| 01:37 ET | 200 | 0.7769 |
| 01:39 ET | 100 | 0.7769 |
| 01:42 ET | 100 | 0.7769 |
| 01:44 ET | 100 | 0.7769 |
| 01:53 ET | 228 | 0.7769 |
| 01:57 ET | 2126 | 0.775 |
| 02:00 ET | 1000 | 0.775 |
| 02:04 ET | 100 | 0.775 |
| 02:08 ET | 100 | 0.775 |
| 02:09 ET | 200 | 0.7716 |
| 02:11 ET | 450 | 0.78 |
| 02:18 ET | 100 | 0.7769 |
| 02:20 ET | 100 | 0.7715 |
| 02:26 ET | 100 | 0.7715 |
| 02:31 ET | 100 | 0.7716 |
| 02:40 ET | 4449 | 0.7696 |
| 02:42 ET | 300 | 0.7787 |
| 02:44 ET | 100 | 0.768 |
| 02:45 ET | 100 | 0.768 |
| 02:47 ET | 300 | 0.7675 |
| 02:49 ET | 200 | 0.7675 |
| 02:51 ET | 100 | 0.7675 |
| 02:54 ET | 100 | 0.7675 |
| 02:56 ET | 213 | 0.7661 |
| 03:03 ET | 410 | 0.7757 |
| 03:09 ET | 3200 | 0.767 |
| 03:12 ET | 100 | 0.767 |
| 03:14 ET | 300 | 0.767 |
| 03:16 ET | 100 | 0.767 |
| 03:18 ET | 200 | 0.767 |
| 03:25 ET | 200 | 0.7735 |
| 03:30 ET | 100 | 0.7696 |
| 03:32 ET | 200 | 0.7696 |
| 03:34 ET | 100 | 0.7774 |
| 03:36 ET | 500 | 0.7696 |
| 03:38 ET | 900 | 0.77 |
| 03:41 ET | 3828 | 0.7737 |
| 03:43 ET | 868 | 0.7737 |
| 03:45 ET | 563 | 0.7769 |
| 03:48 ET | 800 | 0.77 |
| 03:50 ET | 300 | 0.77 |
| 03:52 ET | 300 | 0.7773 |
| 03:54 ET | 350 | 0.7773 |
| 03:56 ET | 1000 | 0.773 |
| 03:57 ET | 7664 | 0.774 |
| 03:59 ET | 2196 | 0.7782 |
Apr 10, 2024
DJ Cara Therapeutics Price Target Maintained With a $5.00/Share by Needham, from 6:45AM ET on Wednesday Apr 10, 2024 by Dow Jones
6:45AM ET on Wednesday Apr 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cara Therapeutics Inc | 42.2M | -0.4x | --- |
ImmuCell Corp | 38.8M | -6.7x | --- |
Prenetics Global Ltd | 65.1M | -1.1x | --- |
Aadi Bioscience Inc | 49.6M | -0.9x | --- |
Turnstone Biologics Corp | 60.4M | -1.0x | --- |
Viaderma Inc | 11.8M | 0.0x | --- |
Company Information
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Contact Information
- Headquarters
- 400 Atlantic Street, Suite 500STAMFORD, CT, United States 06901
- Phone
- 203-406-3700
- Fax
- 203-567-1510
Executives
- Independent Chairman of the Board
- Martin Vogelbaum
- President, Chief Executive Officer, Director
- Christopher Posner
- Chief Financial Officer
- Ryan Maynard
- Senior Vice President - Research and Development, Chief Scientific Officer
- Frederique Menzaghi
- Chief Compliance Officer, General Counsel, Secretary
- Scott Terrillion
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $42.2M |
|---|---|
Revenue (TTM) | $21.0M |
Shares Outstanding | 54.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.81 |
EPS | $-2.19 |
Book Value | $1.05 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 2.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -579.43% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
